Frequency of Hepatobilliary Manifestations in Patients With Inflammatory Bowel Disease

Hepatobilliary Manifestations in Inflammatory Bowel Disease Patients Clinical Trial

Official title:

Frequency of Hepatobilliary Manifestations in Patients With Inflammatory Bowel Disease

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04613479
• Other study ID #: Inflammatory bowel disease
• Status: Not yet recruiting
• Start date: December 1, 2020
• Est. completion date: June 1, 2022

Study information

• Verified date: November 2020
• Source: Assiut University
• Contact: Hussein Elamin
• Phone: 01004084187
• Email: sehshammam[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Hepatobilliary manifestations as extraintestinal manifestations of IBD are sometimes underdiagnosed which can impair patient prognosis

Description:

Non alcoholic fatty liver is aliver disease most commonly found in patient with IBD most commonly without intestinal activity. On the other hand primary according cholangitis is the most common specific with IBD commonly with ulcerative colitis. and is commonly overlap with autoimmune hepatitis IBD therapy can also be a cause it can lead to hepatic toxicity and some drugs like ant TNF can cause hepatitis b virus activation.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 60
• Est. completion date: June 1, 2022
• Est. primary completion date: December 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:all patients diagnosed IBD crohns and ulcerative on conventional treatment and biological treatment - Exclusion Criteria:no -

Related Conditions & MeSH terms

• Hepatobilliary Manifestations in Inflammatory Bowel Disease Patients
• Inflammatory Bowel Diseases
• Intestinal Diseases

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The prevelance of hepatobilliary manifestations in IBD patients		1 year